secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-214711
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva Biotherapeutics raises ~$300M in common stock and pre-funded warrant offering
--------------------------------------------------------------------------------

- Priced 23,871,526 shares at $11.52/share and 2,170,138 pre-funded warrants at $11.5199 each.
- Gross proceeds ~$300M before underwriting discounts and expenses.
- Offering managed by Jefferies, TD Securities, and Cantor Fitzgerald; closing expected May 11, 2026.
- Pre-funded warrants exercisable immediately with 4.99% beneficial ownership cap; cap can be increased to 19.99%.
- Company registered under S-3; shares and warrants listed on Nasdaq under ARTV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526214711/0001193125-26-214711-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526214711/d20969d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-214711

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer